Abstracts Archive - Page 651 of 2607 - ACR Meeting Abstracts

Abstract Number: 1424 • ACR Convergence 2022
Cost-Effectiveness of a Progressive Spacing of Tocilizumab or Abatacept in Patients with Rheumatoid Arthritis in Sustained Remission: A Medico-Economic Analysis of the ToLEDo Trial
Joanna KEDRA¹, Lina El Houari¹, Florence Tubach¹, Benjamin granger¹ and Bruno Fautrel², ¹Sorbonne Université, INSERM, Institut Pierre Louis d’Epidémiologie et de Santé Publique, PEPITES, F75013, Paris, France, Paris, France, ²Sorbonne University Paris, France and Pierre Louis Institute of Epidemiology and Public Health, Paris, France, Paris, France
Background/Purpose: Biologic Disease Modifying Anti-Rheumatic Drugs (bDMARDs) progressive tapering is a real opportunity in people living with rheumatoid arthritis (RA) having achieved remission both from…
Abstract Number: 1402 • ACR Convergence 2022
Late Onset Rheumatoid Arthritis Has a Similar Remission Rate as Younger Onset Rheumatoid Arthritis: Results from an Ontario Rheumatoid Arthritis Registry
Xiuying Li¹, Angela Cesta¹, Mohammad Movahedi² and Claire Bombardier³, ¹University Health Network, Toronto, ON, Canada, ²Toronto General Hospital Research Institute, University Health Network, Toronto, ON, Canada, ³University of Toronto, Toronto, ON, Canada
Background/Purpose: The prevalence of rheumatoid arthritis (RA) in persons 60 years or older is estimated to be 2%. Late onset rheumatoid arthritis (LORA) is a…
Abstract Number: 1454 • ACR Convergence 2022
A High Genetic Risk of SLE Is Associated with an Increased Risk of Myocardial Infarction; A Combined Observational and Mendelian Randomization Study
Sarah Reid¹, Johanna K Sandling¹, Pascal Pucholt¹, Ahmed Sayadi¹, Christopher Sjöwall², Karoline Lerang³, Andreas Jönsen⁴, Anders A Bengtsson⁴, Øyvind Molberg³, Anna Rudin⁵, Solbritt Rantapää-Dahlqvist⁶, Lars Ronnblom⁷ and Dag Leonard¹, ¹Rheumatology and Science for Life Laboratory, Department of Medical Sciences, Uppsala University, Uppsala, Sweden, ²Department of Biomedical and Clinical Sciences, Division of Inflammation and Infection, Linköping University, Linköping, Sweden, ³Department of Rheumatology, Oslo University Hospital, Oslo, Norway, Oslo, Norway, ⁴Department of Clinical Sciences, Lund, Section for Rheumatology, Lund University, Lund and Skåne University Hospital, Lund, Sweden, ⁵Department of Rheumatology and Inflammation Research, Institute of Medicine, Sahlgrenska Academy of University of Gothenburg, Gothenburg, Sweden, ⁶Department of Public Health and Clinical Medicine, Rheumatology, Umeå University, Umeå, Sweden, ⁷Uppsala University, Uppsala, Sweden
Background/Purpose: The reasons for the high cardiovascular morbidity in patients with SLE are not fully understood. Here, we combine a mendelian randomization (MR) approach and…
Abstract Number: 1452 • ACR Convergence 2022
Patterns of Outpatient and Acute Care Use Among Patients with SLE on Long-Term Moderate to High Dose Glucocorticoid Medication: A 1 Year Retrospective Analysis
James Sullivan¹ and Emily Littlejohn², ¹Cleveland Clinic Lerner College of Medicine, Cleveland Heights, OH, ²Cleveland Clinic, Cleveland, OH
Background/Purpose: Long-term glucocorticoid use can lead to adverse outcomes independent of SLE disease activity. Identifying factors associated with long-term glucocorticoids is an important step towards…
Abstract Number: 1457 • ACR Convergence 2022
Baseline Characteristics of a Longitudinal, Multinational, Multiethnic Study of Lupus Patients, with or Without Lupus Nephritis
Romina Nieto¹, Rosana Quintana², eduardo Borba³, Lucia Hernandez⁴, Diana Fernandez-Avila⁵, Laura Maurelli⁶, Paul Alba⁷, Florencia Bordon⁸, Fernando Arizpe⁹, Guillermo Berbotta¹⁰, Rosa Serrano-Morales¹¹, Maria Constanza Bertolaccini¹², Eduardo Kerzberg¹³, Maria Angeles Gargiulo¹⁴, Anabella Rodriguez¹⁵, Vitalina Barbosa¹⁶, Andres gasparin¹⁷, Fernando Cavalcanti¹⁸, Laissa Alves Alvino¹⁹, Luciana Parente Costa Seguro²⁰, Lucas Victoria de Oliveira Martins²¹, oscar Niera²², Loreto Massardo²³, Gustavo Aroca Martinez²⁴, Ivana Nieto Aristizabal²⁵, Paul Mendez Patarroyo²⁶, Antonio iglesias Gamarra²⁴, Andres Zuniga Vera²⁷, Olga-Lidia Vera-Lastra²⁸, Mario Perez Cristobal²⁹, Eduardo Martin-Nares³⁰, Luis M Amezcua-Guerra³¹, Yelitza Gonzalez-Bello³², Octavio Gonzalez Enriquez³³, Dionico Galarzo-Delgado³⁴, Carolina Vazquez³⁵, Marcelo barrios³⁶, Magaly Alba Linares³⁷, Cristina Reategui³⁸, Ana Quiroz-Alva³⁹, Teresandris Polanco Mora⁴⁰, Carina Pizzarossa⁴¹, Martin Rebella⁴², Maria Crespo⁴³, Alvaro Danza⁴⁴, Eloisa Silva Dutra de Oliveira Bonfa⁴⁵, Graciela Alarcón⁴⁶, Federico Zazzetti⁴⁷, Ashley Orillion⁴⁸, Guillermo Pons-Estel⁴⁹ and Urbano Sbarigia⁵⁰ ¹GO-CREAR, Rosario, Santa Fe, Argentina, ²Grupo Oroño - Centro Regional de Enfermedades Autoinmunes y Reumáticas (GO-CREAR), Rosario, Santa Fe, Argentina, ³Rheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, São Paulo, Brazil, ⁴Instituto de Investigaciones Teóricas y Aplicadas. Facultad de Ciencias Económicas y Estadistica. Universidad Nacional de Rosario, Rosario, Argentina, ⁵Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, ⁶Hospital Italiano de Córdoba, Córdoba, Argentina, ⁷Rheumatology Unit, Internal Medicine Service, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, ⁸Hospital Privado Universitario de Córdoba, Cordoba, Argentina, ⁹Hospital HIGA San Martín, San Martín, Argentina, ¹⁰Sanatorio Británico, Rosario, Argentina, ¹¹Sanatorio Parque. Centro de Enfermedades Autoinmunes y Reumáticas del Grupo Oroño, Rosario, Argentina, ¹²Hospital Padilla, San Miguel de Tucuman, Argentina, ¹³Hospital General de Agudos Dr. Ramos Mejia, Buenos Aires, Argentina, ¹⁴Instituto de Investigaciones Médicas Alfredo Lanari, Buenos Aires, Argentina, ¹⁵CEMIC, Galvan, Argentina, ¹⁶Universidade Federal de Goiás, Goiana, Brazil, ¹⁷Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil, ¹⁸Universidad Federal de Pernambuco, Recife, Brazil, ¹⁹Hospital Universitario Pedro Ernesto, UERJ, Rio de Janiero, Brazil, ²⁰Hospital das Clínicas, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, ²¹Universidad Federal São Paulo, São Paulo, Brazil, ²²Hospital del Salvador, Providencia, Chile, ²³Universidad San Sebastián, Santiago de Chile, Chile, ²⁴Clínica de la Costa Ltda., Barranquilla, Colombia, ²⁵Fundación Valle del Lili, Calí, Colombia, ²⁶Fundación Santa Fe, Bogotá, Colombia, ²⁷Hospital Luis Vernaza, Guayaquil, Ecuador, ²⁸Centro Médico La Raza, Ciudad de México, Mexico, ²⁹Centro Médico Nacional Siglo XXI, Ciudad de México, Mexico, ³⁰Department of Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Ciudad de México, Mexico, ³¹Instituto Nacional de Cardiología Ignacio Chávez, Ciudad de México, Mexico, ³²Centro de Estudios de investigación Básica y Clínica S.C, Jalisco, Mexico, ³³Hospital Central Dr. Ignacio Morones Prieto, San Luis, Mexico, ³⁴Hospital Universitario "Dr. José Eleuterio Gonzalez", Monterrey, Mexico, ³⁵Hospital de Clínicas I, Montevideo, Uruguay, ³⁶Hospital de Clínicas II, Montevideo, Uruguay, ³⁷Hospital Nacional Edgardo Rebagliatti Martins, Lima, Peru, ³⁸Hospital Nacional Guillermo Almenara Irigoyen. EsSalud, Lima, Peru, ³⁹Hospital Cayetano Heredia, San Martín de Porres District, Peru, ⁴⁰Hospital Docente Padre Billini, Santo Domingo, Dominican Republic, ⁴¹Clínica Médica C, Hospital de Clínicas, UDELAR, Montevideo, Uruguay, ⁴²Departamento de Medicina, Facultad de Medicina, Universidad de la República, Montevideo, Uruguay, ⁴³Hospital Señor del Milagro, Salta, Argentina, ⁴⁴Grupo de Investigacion de EAIS y Reumatológicas, A Coruña, Spain, ⁴⁵Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de São Paulo, São Paulo, Brazil, ⁴⁶The University of Alabama at Birmingham, Oakland, ⁴⁷Janssen Medical Affairs Global Services, LLC, Buenos Aires, Argentina, ⁴⁸Janssen, Horsham, PA, ⁴⁹CREAR, Rosario, Argentina, ⁵⁰Johnson & Johnson, Beerse, Belgium
Background/Purpose: Clinically evident kidney disease eventually occurs in up to one-half of SLE patients. The aim of this study is to describe sociodemographic, clinical, serological…
Abstract Number: 1456 • ACR Convergence 2022
Latin-American Systemic Lupus Erythematosus Clusters
Rosana Quintana¹, Romina Nieto², Marina Scolnik³, Nidia Meras⁴, Cintia Otaduy⁵, María Emilia Sattler⁶, Luciana González Lucero⁷, Nicolas Perez⁸, Ana Silva⁹, Odirlei Monticielo¹⁰, Angela Luzia B Duarte¹¹, Edgard Reis Neto¹², Milena Mimica¹³, Gustavo Aroca Martinez¹⁴, Gerardo Quintana-Lopez¹⁵, Mario Moreno Alvarez¹⁶, Miguel Angel Saavedra Salinas¹⁷, Margarita Portela¹⁸, Luis H Silveira¹⁹, Ignacio García Valladares²⁰, Carlos Abud-Mendoza²¹, Jorge Esquivel-Valerio²², Maria Duarte²³, Roberto Muñoz Louis²⁴, Vicente Juárez²⁵, Eduardo Ferreira Borba Neto²⁶, Luis Catoggio²⁷, Graciela Alarcón²⁸, Jose Puerta²⁹, Guillermina Harvey³⁰, Elisa Novati³¹, Valeria Arturi³², Wilfredo Grageda³³, Cecilia Pisoni³⁴, Francinne Machado Riobeiro³⁵, Emily Figueiredo Neves Yuki²⁶, Iris Guerra Herrera³⁶, Gabriel Tobón³⁷, Andres Cadena Bonfanti¹⁴, Hilda Fragoso-Loyo³⁸, Marie Teresa de Martinez³⁹, Claudia Selene Mora Trujillo⁴⁰, Manuel Ugarte-Gil⁴¹, Ernesto Zavala Flores⁴², Ricardo Robaina⁴³, Gonzalo Silveira⁴⁴, Federico Zazzetti⁴⁵, Ashley Orillion⁴⁶, Guillermo Pons-Estel⁴⁷, Bernardo Pons-Estel² and Urbano Sbarigia⁴⁸, ¹Grupo Oroño - Centro Regional de Enfermedades Autoinmunes y Reumáticas (GO-CREAR), Rosario, Santa Fe, Argentina, ²Grupo Oroño - Centro Regional de Enfermedades Autoinmunes y Reumáticas (GO-CREAR), Rosario, Argentina, ³Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, ⁴Hospital Italiano de Córdoba, Cordoba, Argentina, ⁵Hospital Córdoba, Córdoba, Argentina, ⁶Sanatorio Británico, Paraná, Argentina, ⁷Hospital Padilla, San Miguel de Tucumán, Argentina, ⁸Instituto Lanari, Buenos Aires, Argentina, ⁹Hospital das Clinicas, Univerisad Federal de Goias, Goiania, Brazil, ¹⁰Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil, ¹¹Universidade Federal de Pernambuco, Recife, Brazil, ¹²Universidad Federal São Paulo, São Paulo, Brazil, ¹³Universidad San Sebastián, Santiago, Chile, ¹⁴Clínica de la Costa Ltda., Barranquilla, Colombia, ¹⁵Reumavance Group, Rheumatology section, Department of Internal Medicine, Fundación Santa Fe de Bogotá University Hospital. Bogota, Colombia; Department of Internal Medicine, School of Medicine, Universidad Nacional de Colombia. Bogota, Colombia; Department of Internal Medicine. School of Medicine, Universidad de Los Andes, Bogotá, Colombia, ¹⁶Hospital Luis Vernaza, Guayaquil, Ecuador, ¹⁷IMSS, Ciudad de México, Mexico, ¹⁸Centro Médico Nacional Siglo XXI, Ciudad de México, Mexico, ¹⁹Instituto Nacional de Cardiología, Ciudad de México, Mexico, ²⁰CEIBAC, SC, Guadalajara, Mexico, ²¹Hospital Central and Faculty of Medicine, UASLP, San Luis Potosí, Mexico, ²²Hospital Universitario “Dr. José Eleuterio Gonzalez", Monterrey, Mexico, ²³Hospital de Clínicas Paraguay, Asunción, Paraguay, ²⁴Hospital Docente Padre Billini, Santo Domingo, Dominican Republic, ²⁵MSP, Salta, Argentina, ²⁶Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de São Paulo, São Paulo, Brazil, ²⁷Hospital Italiano de Buenos Aires, Olivos, Argentina, ²⁸The University of Alabama at Birmingham, Oakland, ²⁹Rheumatology Department, Hospital Clinic, University of Barcelona, Barcelona, Spain, ³⁰Instituto de Investigaciones Teóricas y Aplicadas. Facultad de Ciencias Económicas y Estadistica. Universidad Nacional de Rosario, Santa Fe, Argentina, ³¹Hospital Privado Universitario de Córdoba, Cordoba, Argentina, ³²Hospital HIGA San Martín, Buenos Aires, Argentina, ³³Hospital General de Agudos J.M. Ramos Mejía, Buenos Aires, Argentina, ³⁴CEMIC- Centro de Educación Médica e Investigaciones Clínicas, Buenos Aires, Argentina, ³⁵Hospital Universitario Pedro Ernesto, UERJ, Rio de Janiero, Brazil, ³⁶Hospital del Salvador, Santiago, Chile, ³⁷Fundación Valle del Lili, Calí, Colombia, ³⁸Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Ciudad de México, Mexico, ³⁹Hospital de Clínicas I, Montevideo, Uruguay, ⁴⁰Hospital Nacional Edgardo Rebagliatti Martins, Lima, Peru, ⁴¹Hospital Nacional Guillermo Almenara Irigoyen, Lima, Peru, ⁴²Hospital Cayetano Heredia, San Martín de Porres Distric, Peru, ⁴³Clínica Médica C, Hospital de Clínicas, UDELAR, Montevideo, Uruguay, ⁴⁴Grupo de Investigacion de EAIS y Reumatológicas, A Coruña, Spain, ⁴⁵Janssen Medical Affairs Global Services, LLC, Buenos Aires, Argentina, ⁴⁶Janssen, Horsham, PA, ⁴⁷CREAR, Rosario, Argentina, ⁴⁸Johnson & Johnson, Beerse, Belgium
Background/Purpose: Systemic lupus erythematosus (SLE) is a complex and heterogeneous autoimmune disease. The identification of patient subgroups or clusters may be useful for the management…
Abstract Number: 1459 • ACR Convergence 2022
Evolution of Subjective Cognitive Impairment Overtime in SLE Patients: Bayesian Longitudinal Item Response Theory Modelling
Michelle Barraclough¹, Juan Pablo Diaz-Martinez², Andrea Knight³, Kathleen Bingham⁴, Jiandong Su², Mahta Kakvan⁵, Carolina Munoz², Maria Carmela Tartaglia⁶, Leslet Ruttan⁷, Joan Wither⁵, May Choi⁸, Nicole Anderson⁹, Dennisse Bonilla², Simone Appenzeller¹⁰, Ben Parker¹¹, Patricia Katz¹², Dorcas Beaton¹³, Robin Green⁷, Ian N. Bruce¹⁴ and Zahi Touma², ¹Schroeder Arthritis Institute, Krembil Research Institute, University Health Network, Centre for Epidemiology Versus Arthritis, Division of Musculoskeletal and Dermatological Sciences, School of Biological Sciences, Faculty of Biology, Medicine and Health, The University of Manchester, NIHR Manchester Biomedical Research Centre, Manchester University NHS Foundation Trust, Manchester Academic Health Science Centre, Toronto, ON, Canada, ²Schroeder Arthritis Institute, Krembil Research Institute, University Health Network and University of Toronto, Toronto, ON, Canada, ³The Hospital for Sick Children, Division of Rheumatology, Department of Paediatrics, University of Toronto, Toronto, ON, Canada, ⁴Centre for Mental Health, University Health Network; Department of Psychiatry, University of Toronto, Toronto, ON, Canada, ⁵Schroeder Arthritis Institute, Krembil Research Institute, University Health Network, University of Toronto, Toronto, ON, Canada, ⁶University of Toronto Krembil Neurosciences Centre, Toronto, ON, Canada, ⁷University Health Network-Toronto Rehabilitation Institute, Toronto, ON, Canada, ⁸Brigham and Women's Hospital | University of Calgary, Calgary, AB, Canada, ⁹Schroeder Arthritis Institute, Krembil Research Institute and University Health Network, University of Toronto, Toronto, ON, Canada, ¹⁰Unicamp, Campinas, São Paulo, Brazil, ¹¹Manchester University Hospitals NHS Foundation Trust, Manchester, United Kingdom, ¹²UCSF, San Rafael, CA, ¹³Institute for Work & Health, Toronto, ON, Canada, ¹⁴Centre for Epidemiology Versus Arthritis, Faculty of Biology, Medicine and Health, The University of Manchester, Manchester, United Kingdom
Background/Purpose: Subjective cognitive impairment (SCI) is a significant problem in SLE and there are a lack of studies assessing change over time in SCI. The…
Abstract Number: 1458 • ACR Convergence 2022
Systemic Lupus Erythematosus (SLE) Patients with Cognitive Impairment Experience More Fatigue Compared to Patients Without Impairment
Delansie Lawrence¹, Jiandong Su¹, Andrea Knight², Kathleen Bingham³, Mahta Kakvan¹, Maria Carmela Tartaglia⁴, Leslet Ruttan⁵, Joan Wither⁶, May Choi⁷, Simone Appenzeller⁸, Nicole Anderson¹, Dennisse Bonilla¹, Patricia Katz⁹, Dorcas Beaton¹⁰, Robin Green⁵, Zahi Touma¹ and Michelle Barraclough¹¹, ¹Schroeder Arthritis Institute, Krembil Research Institute, University Health Network and University of Toronto, Toronto, ON, Canada, ²The Hospital for Sick Children, Division of Rheumatology, Department of Paediatrics, University of Toronto, Toronto, ON, Canada, ³Centre for Mental Health, University Health Network; Department of Psychiatry, University of Toronto, Toronto, ON, Canada, ⁴University of Toronto Krembil Neurosciences Centre, Toronto, ON, Canada, ⁵University Health Network-Toronto Rehabilitation Institute, Toronto, ON, Canada, ⁶Schroeder Arthritis Institute, Krembil Research Institute, University Health Network, University of Toronto, Toronto, ON, Canada, ⁷Brigham and Women's Hospital | University of Calgary, Calgary, AB, Canada, ⁸Unicamp, Campinas, São Paulo, Brazil, ⁹UCSF, San Rafael, CA, ¹⁰Institute for Work & Health, Toronto, ON, Canada, ¹¹Schroeder Arthritis Institute, Krembil Research Institute, University Health Network, University of Toronto, Centre for Epidemiology Versus Arthritis, Division of Musculoskeletal and Dermatological Sciences, School of Biological Sciences, Faculty of Biology, Medicine and Health, The University of Manchester, NIHR Manchester Biomedical Research Centre, Manchester University NHS Foundation Trust, Manchester Academic Health Science Centre, Toronto, ON, Canada
Background/Purpose: Cognitive impairment (CI) is highly prevalent in patients with systemic lupus erythematosus (SLE). Objective prevalence rates are reported as 38% [range: 20% to 80%]…
Abstract Number: 1460 • ACR Convergence 2022
Neuropsychiatric Lupus in Late and Early Onset Systemic Lupus Erythematosus Patients: A Systemic Review and Meta-analysis
Omer Pamuk¹, Saja Ali² and Sarfaraz Hasni², ¹NIH/NIAMS, Bethesda, MD, ²NIAMS/NIH, Bethesda, MD
Background/Purpose: The diagnosis of neuropsychiatric lupus (NPSLE) is challenging due to its variegated presentation, absence of diagnostic biomarkers and radiological imaging. The NPSLE is further…
Abstract Number: 1462 • ACR Convergence 2022
Exploring the Potential of Urine: Serum Fractional Excretion Ratios as Disease Biomarkers in Active Lupus Nephritis
Samar Soliman¹, Samantha Stanley², Kamala Vanarsa², Faten Ismail³, Chi Chiu Mok⁴ and Chandra mohan⁵, ¹Rheumatology Department, Faculty of Medicine, Minia university, Minya, Egypt, ²Department of Biomedical Engineering, University of Houston, Houston, TX, ³Department of Rheumatology, Faculty of Medicine, Minia University, Minia, Egypt, ⁴Tuen Mun Hospital, Hong Kong, China, ⁵University of Houston, Houston, TX
Background/Purpose: The goal of this exploratory study is to determine if urine:serum fractional excretion ratios can outperform the corresponding urinary biomarker proteins in identifying active…
Abstract Number: 1449 • ACR Convergence 2022
Incidence and Risk Factors for Active Tuberculosis in Patients with Systemic Lupus Erythematosus: A Multicenter Prospective Cohort Study
Lifan Zhang¹, xiaoqing zou², Lantian Xie³, Jianghao Liu³, zhengrong yang⁴, qifei cao⁴, Chunlei Li⁵, Xiaochuan Sun⁵, Fengchun ZHANG⁶, Yan Zhao⁷, Xiaofeng Zeng⁸ and Xiaoqing Liu¹, ¹Division of Infectious Diseases, Department of Internal medicine, State Key Laboratory of Complex Severe and Rare Disease, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College; Clinical Epidemiology Unit, Peking Union Medical College, International Clinical Epidemiology Network; Center for Tuberculosis Research, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China, ²Division of Infectious Diseases, Department of Internal medicine, State Key Laboratory of Complex Severe and Rare Disease, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College; School of Population Medicine and Public Health, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China, ³Peking Union Medical College Hospital, Peking Union Medical College, Beijing, China, ⁴Division of Infectious Diseases, Department of Internal medicine, State Key Laboratory of Complex Severe and Rare Disease, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China, ⁵Department of Internal medicine, State Key Laboratory of Complex Severe and Rare Disease, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China, ⁶Peking Union Medical College Hospital, Beijing, China, ⁷Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Key Laboratory of Rheumatology & Clinical Immunology, Ministry of Education, Beijing, China, ⁸Department of Rheumatology, Peking Union Medical College Hospital (PUMCH), Chinese Academy of Medical Sciences National Clinical Research Center for Dermatologic and Immunologic Diseases (NCRC-DID), Beijing, China
Background/Purpose: The burden of tuberculosis (TB) and systemic lupus erythematosus (SLE) in China are both the second largest in the world. Patients with SLE are…
Abstract Number: 1464 • ACR Convergence 2022
Patients with Late-onset-Systemic Lupus Erythematosus Have Different Disease Presentations
Ganiat Adeogun, Alex Camai, Sarah Green and April Barnado, Vanderbilt University Medical Center, Nashville, TN
Background/Purpose: Systemic lupus erythematosus (SLE) predominantly affects females of reproductive age but can affect patients later in life. Late-onset (LO)-SLE is defined as SLE diagnosed…
Abstract Number: 1465 • ACR Convergence 2022
Clinical Profiling and Antiphospholipid Antibody (aPL) Associations in Indian Systemic Lupus Erythematosus (SLE) Cohort
Vineeta Shobha¹, Liza Rajasekhar², Sandra Manuel¹, Chengappa Kavadichanda³, Ashish J Mathew⁴, Ranjan Gupta⁵, Manish Rathi⁶, Parasar Ghosh⁷, Saumya Ranjan Tripathy⁸, Avinash Jain⁹ and Amita Aggarwal¹⁰, ¹St. John’s Medical College Hospital, Bangalore, India, ²Nizam's Institute of Medical Sciences, Madhapur, India, ³JIPMER, Pondicherry, Puducherry, India, ⁴Rigshospitalet, Copenhagen, Denmark, ⁵All India Institute of Medical Sciences, New Delhi, India, ⁶PGIMER Chandigarh, Chandigarh, India, ⁷Govt of West Bengal, Kolkata, India, Kolkata, West Bengal, India, ⁸SCB medical college, Cuttack, India, ⁹SMS Medical College, Lucknow, India, ¹⁰Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India
Background/Purpose: Antiphospholipid Antibody (aPL) are described in 11-40% of patients with SLE. Whether the presence of any of the aPLs or combinations thereof, can accurately…
Abstract Number: 1467 • ACR Convergence 2022
Dickkopf Homolog 3 (DKK3) as a Prognostic Marker in Lupus Nephritis: A Prospective Monocentric Experience
Savino Sciascia¹, Alice Barinotti², Massimo Radin², Irene Cecchi¹, Elisa Menegatti², Vittorio Modena², Daniela Rossi², Simone Baldovino², Roberta Fenoglio² and Dario Roccatello², ¹University of Turin, Torino, Italy, ²University of Turin, Turin, Italy
Background/Purpose: Lupus Nephritis (LN) is a major cause of mortality/morbidity in patients affected by Systemic Lupus Erythematosus (SLE). Reliable prognostic markers, especially related to the…
Abstract Number: 1468 • ACR Convergence 2022
Apathy Measurement in a Cohort of Systemic Lupus Erythematosus
Mike Putman¹, David Gazeley² and Ikechukwu Mbonu³, ¹The Medical College of Wisconsin, Milwaukee, WI, ²Medical College of Wisconsin, Wauwatosa, WI, ³Medical College of Wisconsin, Milwaukee, WI
Background/Purpose: Up to 40% of patients with systemic lupus erythematosus (SLE) have measurable cognitive dysfunction on neuropsychiatric testing. Around 83% of patients are nonadherent with…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].